146 related articles for article (PubMed ID: 24942396)
1. Patients benefit from genetics-guided coumarin anticoagulant therapy.
Maitland-van der Zee AH; Daly AK; Kamali F; Manolopoulous VG; Verhoef TI; Wadelius M; de Boer A; Pirmohamed M;
Clin Pharmacol Ther; 2014 Jul; 96(1):15-7. PubMed ID: 24942396
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and coumarin dosing--recalibrating expectations.
Zineh I; Pacanowski M; Woodcock J
N Engl J Med; 2013 Dec; 369(24):2273-5. PubMed ID: 24328463
[No Abstract] [Full Text] [Related]
6. Genotype-guided dosing of vitamin K antagonists.
Pirmohamed M; Wadelius M; Kamali F;
N Engl J Med; 2014 May; 370(18):1764-5. PubMed ID: 24804303
[No Abstract] [Full Text] [Related]
7. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
8. Genotype-guided dosing of vitamin K antagonists.
Maitland-van der Zee AH; de Boer A; Manolopoulos VG;
N Engl J Med; 2014 May; 370(18):1765-6. PubMed ID: 24804306
[No Abstract] [Full Text] [Related]
9. Genotype-guided dosing of vitamin K antagonists.
Cavallari LH; Kittles RA; Perera MA
N Engl J Med; 2014 May; 370(18):1763. PubMed ID: 24785218
[No Abstract] [Full Text] [Related]
10. Genotype-guided dosing of vitamin K antagonists.
Koller EA; Roche JC; Rollins JA
N Engl J Med; 2014 May; 370(18):1761. PubMed ID: 24785214
[No Abstract] [Full Text] [Related]
11. Genotype-guided dosing of vitamin K antagonists.
Kimmel SE; French B; Geller NL;
N Engl J Med; 2014 May; 370(18):1763-4. PubMed ID: 24785213
[No Abstract] [Full Text] [Related]
12. Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
Furie B
N Engl J Med; 2013 Dec; 369(24):2345-6. PubMed ID: 24251364
[No Abstract] [Full Text] [Related]
13. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
[TBL] [Abstract][Full Text] [Related]
14. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
[TBL] [Abstract][Full Text] [Related]
15. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation therapy: genotype-guided anticoagulation therapy-the jury is still out.
Roberts A
Nat Rev Cardiol; 2014 Jan; 11(1):1. PubMed ID: 24302217
[No Abstract] [Full Text] [Related]
18. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
Schwarz UI; Stein CM
Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312
[No Abstract] [Full Text] [Related]
19. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.
Becquemont L
Eur J Clin Pharmacol; 2008 Oct; 64(10):953-60. PubMed ID: 18758764
[TBL] [Abstract][Full Text] [Related]
20. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
